Literature DB >> 26114083

PATHOGENESIS OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN NON ALCOHOLIC FATTY LIVER DISEASE.

Kirti Shetty1, Jian Chen2, Ji-Hyun Shin2, Wilma Jogunoori3, Lopa Mishra2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is being recognized as an increasingly important contributor to the burden of hepatocellular carcinoma (HCC) worldwide. It is often accompanied by obesity and diabetes mellitus and is believed to be the hepatic representation of the metabolic syndrome. HCC development in NAFLD is multifactorial and complex. It is dependent on not only the well-described mechanisms noted in chronic liver injury, but also on the molecular derangements associated with obesity and dysmetabolism. These include adipocyte remodeling, adipokine secretion, lipotoxicity and insulin resistance. Recent advances focus on the importance of the gut-liver axis in accelerating the process of oncogenesis in NAFLD. The farnesoid X nuclear receptor (FXR) has been demonstrated to have important metabolic effects and its pharmacological activation by obeticholic acid has been recently reported to produce histological improvement in NASH. It is hoped that delineating the mechanisms of hepatic fibrosis and oncogenesis in NASH will lead to enhanced strategies for cancer prevention, surveillance and therapy in this population.

Entities:  

Keywords:  Hepatocellular carcinoma; non-alcoholic fatty liver disease; pathogenesis

Year:  2015        PMID: 26114083      PMCID: PMC4476538          DOI: 10.1007/s11901-015-0260-z

Source DB:  PubMed          Journal:  Curr Hepatol Rep        ISSN: 2195-9595


  69 in total

1.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

2.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

3.  Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease.

Authors:  Giovanni Targher; Lorenzo Bertolini; Luca Scala; Massimo Cigolini; Luciano Zenari; Giancarlo Falezza; Guido Arcaro
Journal:  Nutr Metab Cardiovasc Dis       Date:  2006-08-22       Impact factor: 4.222

Review 4.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

5.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

6.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

8.  Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.

Authors:  Neeraj K Saxena; Dipali Sharma; Xiaokun Ding; Songbai Lin; Fabio Marra; Didier Merlin; Frank A Anania
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

9.  Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort.

Authors:  S Schlesinger; K Aleksandrova; T Pischon; M Jenab; V Fedirko; E Trepo; K Overvad; N Roswall; A Tjønneland; M C Boutron-Ruault; G Fagherazzi; A Racine; R Kaaks; V A Grote; H Boeing; A Trichopoulou; M Pantzalis; M Kritikou; A Mattiello; S Sieri; C Sacerdote; D Palli; R Tumino; P H Peeters; H B Bueno-de-Mesquita; E Weiderpass; J R Quirós; R Zamora-Ros; M J Sánchez; L Arriola; E Ardanaz; M J Tormo; P Nilsson; B Lindkvist; M Sund; O Rolandsson; K T Khaw; N Wareham; R C Travis; E Riboli; U Nöthlings
Journal:  Ann Oncol       Date:  2013-05-29       Impact factor: 32.976

10.  Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study.

Authors:  Veronika Fedirko; Talita Duarte-Salles; Christina Bamia; Antonia Trichopoulou; Krasimira Aleksandrova; Dimitrios Trichopoulos; Elisabeth Trepo; Anne Tjønneland; Anja Olsen; Kim Overvad; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Marina Kvaskoff; Tilman Kühn; Annie Lukanova; Heiner Boeing; Brian Buijsse; Eleni Klinaki; Chrysanthi Tsimakidi; Alessio Naccarati; Giovanna Tagliabue; Salvatore Panico; Rosario Tumino; Domenico Palli; H Bas Bueno-de-Mesquita; Peter D Siersema; Petra H Peters; Eiliv Lund; Magritt Brustad; Karina Standahl Olsen; Elisabete Weiderpass; Raul Zamora-Ros; María-José Sánchez; Eva Ardanaz; Pilar Amiano; Carmen Navarro; J Ramón Quirós; Mårten Werner; Malin Sund; Björn Lindkvist; Johan Malm; Ruth C Travis; Kay-Tee Khaw; Magdalena Stepien; Augustin Scalbert; Isabelle Romieu; Pagona Lagiou; Elio Riboli; Mazda Jenab
Journal:  Hepatology       Date:  2014-08-28       Impact factor: 17.425

View more
  4 in total

Review 1.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

Review 2.  Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis.

Authors:  Bei Li; Chuan Zhang; Yu-Tao Zhan
Journal:  Can J Gastroenterol Hepatol       Date:  2018-07-02

3.  Metabolic syndrome and the incidence of hepatocellular carcinoma: a meta-analysis of cohort studies.

Authors:  Yongxin Chen; Xiaofei Li; Shuang Wu; Weiwei Ye; Lianqing Lou
Journal:  Onco Targets Ther       Date:  2018-09-27       Impact factor: 4.147

Review 4.  Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?

Authors:  Ângelo Z Mattos; Jose D Debes; Arndt Vogel; Marco Arrese; Xavier Revelo; Tales Henrique S Pase; Muriel Manica; Angelo A Mattos
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.